Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG001 (Enlonstobart) in advanced tumors
NCT03852823Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2019
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of PBI-1308 in solid tumor (advanced stage), Cervical Cancer (CC), malignant mesothelioma and 2 more (6 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-Limiting Toxicity at 21 days, Objective Response Rate up to 2 years and 1 more. Status: unknown.
02
Drugs
PBI-1308
03
Conditions
solid tumor (advanced stage)Cervical Cancer (CC)malignant mesotheliomalymphomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03852823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852823.